Article

Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: A single-center retrospective analysis

2023-08-04

Abstract excerpt

Currently, combining chemotherapy with Bruton tyrosine kinase inhibitors (BTKi) has demonstrated significant effectiveness in treating patients with diffuse large B-cell lymphoma (DLBCL). Orelabrutinib is a second-generation BTK inhibitor and presently, there have been few reports of Orelabrutinib being used to treat DLBCL. We conducted a retrospective investigation to explore the safety and efficacy of Orelabruti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 453111ae-3bbb-535f-91e6-1359c59b0e9b
DOI: 10.21203/rs.3.rs-3199662/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: A single-center retrospective analysisDOI 10.21203/rs.3.rs-3199662/v1Read

Orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients: Multi-center, Single-arm, Open-label, Phase 2 StudySemantic proximity Read

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity Read

Efficacy of BTK inhibitor administered for central high-risk systemic diffuse large B cell lymphoma and primary central nervous system lymphoma: A single-center retrospective studySemantic proximity Read

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial.Semantic proximity Read

Double-Hit Large B Cell Lymphoma.Semantic proximity Read

Diffuse large B cell lymphoma: molecular targeted therapy.Semantic proximity Read

The treatment of Burkitt lymphoma in adults.Semantic proximity Read

Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.Semantic proximity Read

TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma.Semantic proximity Read

Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and BeyondSemantic proximity Read

Burkitt lymphoma: bridging the gap between advances in molecular biology and therapySemantic proximity Read

Drug therapy for double-hit lymphomaSemantic proximity Read